stockrowMedpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) Free cash flow margin
Medpace Holdings, Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 23.5%, down 3.4 percentage points from fiscal 2025 (27.0%). Over the past ten years it has ranged from 18.6% (fiscal 2016) to 27.1% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 27.0% | (0.18) |
| FY2024 | 27.1% | 6.09 |
| FY2023 | 21.0% | (3.01) |
| FY2022 | 24.1% | 3.47 |
| FY2021 | 20.6% | (3.97) |
| FY2020 | 24.6% | 3.18 |
| FY2019 | 21.4% | 1.42 |
| FY2018 | 20.0% | 0.44 |
| FY2017 | 19.5% | 0.96 |
| FY2016 | 18.6% | (3.56) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| MEDP Medpace Holdings, Inc. | 23.5% |
| ILMN Illumina, Inc. compare | 23.3% |
| QGEN QIAGEN N.V. compare | 21.0% |
| RVTY Revvity Inc. compare | 20.5% |
| DGX Quest Diagnostics Incorporated compare | 11.6% |
| ICLR ICON PLC compare | 10.4% |
| CRL Charles River Laboratories International, Inc. compare | 10.1% |
| LH Labcorp Holdings Inc. compare | 8.87% |
| GH Guardant Health, Inc. compare | −18.2% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on MEDP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement